Cargando…

Recent developments in the treatment of small cell lung cancer

Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment remained relatively unchanged, with chemotherapy remaining the cornerstone of treatment. In this overview we will highlight t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiddinga, Birgitta I., Raskin, Jo, Janssens, Annelies, Pauwels, Patrick, Van Meerbeeck, Jan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488550/ https://www.ncbi.nlm.nih.gov/pubmed/34261744 http://dx.doi.org/10.1183/16000617.0079-2021

Ejemplares similares

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
por: Hiddinga, Birgitta, et al.
Publicado: (2022)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

Imaging of urgencies and emergencies in the lung cancer patient
por: De Potter, Bruno, et al.
Publicado: (2018)

Mesothelioma treatment: Are we on target? A review
por: Hiddinga, Birgitta I., et al.
Publicado: (2015)

The seventh tumour–node–metastasis staging system for lung cancer: Sequel or prequel?
por: van Meerbeeck, Jan P., et al.
Publicado: (2013)

Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?
por: Hiddinga, Birgitta I., et al.
Publicado: (2021)

New Implications of Patients’ Sex in Today’s Lung Cancer Management
por: Raskin, Jo, et al.
Publicado: (2022)

Cancer in the time of COVID-19: expert opinion on how to adapt current practice
por: Raskin, Jo, et al.
Publicado: (2020)

Optimal approach for upfront resectable non-small-cell lung cancer
por: van Meerbeeck, Jan P.
Publicado: (2013)

Novel teatment options in early-stage non-small-cell lung cancer
por: van Meerbeeck, Jan P.
Publicado: (2013)

Surgical series in mesothelioma: navigating between biases
por: Raskin, Jo, et al.
Publicado: (2023)

Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy—The Role of Liquid Biopsy in Unraveling the Puzzle
por: Augustus, Elien, et al.
Publicado: (2021)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Lung cancer screening in Europe: where are we in 2021?
por: van Meerbeeck, Jan P., et al.
Publicado: (2021)

Prognostic implications of cellular senescence in resected non-small cell lung cancer
por: Domen, Andreas, et al.
Publicado: (2022)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
por: Janssens, Eline, et al.
Publicado: (2022)

Lung Cancer Screening: New Perspective and Challenges in Europe
por: Van Meerbeeck, Jan P., et al.
Publicado: (2022)

Recent advances in the treatment of non-small cell and small cell lung cancer
por: Stinchcombe, Thomas E.
Publicado: (2014)

A Cross-Sectional Study on the Acceptability of Implementing a Lung Cancer Screening Program in Belgium
por: Diab Garcia, Paloma, et al.
Publicado: (2022)

Recent advances in the management of non-small cell lung cancer
por: Shojaee, Samira, et al.
Publicado: (2017)

Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient
por: De Bondt, Charlotte, et al.
Publicado: (2020)

A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression
por: De Bondt, Charlotte, et al.
Publicado: (2020)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

Obstetrical research in The Netherlands in the nineteenth century.
por: Hiddinga, A
Publicado: (1987)

Een eeuw vrouwenarts
por: Hiddinga, Anja
Publicado: (1989)

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions
por: Castelo-Branco, L., et al.
Publicado: (2023)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Do-not-resuscitate orders as part of advance care planning in patients with COPD
por: Raskin, Jo, et al.
Publicado: (2018)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

A critical review of recent developments in radiotherapy for non-small cell lung cancer
por: Baker, Sarah, et al.
Publicado: (2016)

Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study
por: Baas, P, et al.
Publicado: (2006)

Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer
por: Claes, Erik, et al.
Publicado: (2023)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
por: Cuppens, Kristof, et al.
Publicado: (2021)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments
por: Gupta, Chetna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hohbm4ci3o3hmqut1svlkhabs8